Eric S. Furfine

5.3k citations

73 papers · 4.3k indexed · 1 hit paper · h-index 33

Co-authors: Edward P. Garvey Jeffrey A. Oplinger John E. Reardon Richard G. Knowles B.J.R. Whittle Ferenc László Lois L. Wright Andrew Spaltenstein
Topics: HIV/AIDS drug development and treatment (32 papers)HIV Research and Treatment (24 papers)Nitric Oxide and Endothelin Effects (10 papers)
Cited by: Virology Infectious Diseases Biochemistry
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Biological Chemistry
Partner nations: United States United Kingdom India

In The Last Decade

Eric S. Furfine

73 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo

1997 727 citations Edward P. Garvey, Jeffrey A. Oplinger et al. Journal of Biological Chemistry profile →

Peers

Countries citing papers authored by Eric S. Furfine

Since Specialization

Citations

This map shows the geographic impact of Eric S. Furfine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric S. Furfine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric S. Furfine more than expected).

Fields of papers citing papers by Eric S. Furfine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric S. Furfine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric S. Furfine. The network helps show where Eric S. Furfine may publish in the future.

Co-authorship network of co-authors of Eric S. Furfine

This figure shows the co-authorship network connecting the top 25 collaborators of Eric S. Furfine. A scholar is included among the top collaborators of Eric S. Furfine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric S. Furfine. Eric S. Furfine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pegylated CB2782: a Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD 2019 ·Investigative Ophthalmology & Visual Science ·Eric S. Furfine,Anjali Rao,(unknown),(unknown),(unknown),(unknown),Grant E. Blouse,(unknown),(unknown)	2
2	Discovery and Planned Optimization of a Complement Factor C3-Inactivating Alterase, CB-2782 2018 ·Investigative Ophthalmology & Visual Science ·Eric S. Furfine,Martin Stanton,(unknown),Nassim Usman,David L. Sloane,Mikhail Popkov,Edwin L. Madison	1
3	Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease 2016 ·Eye & Contact Lens Science & Clinical Practice ·Michael H. Goldstein,Joseph R. Martel,Kenneth Sall,Damien F. Goldberg,(unknown),(unknown),John D. Sheppard,Joseph Tauber,Michael Korenfeld,(unknown),Todd A. Durham,Eric S. Furfine	19
4	Optimized intravitreal IL-6 antagonist for the treatment of diabetic macular edema 2015 ·Investigative Ophthalmology & Visual Science ·Michael Schmidt,(unknown),(unknown),(unknown),(unknown),Paul Y K Wu,(unknown),(unknown),(unknown),Eric S. Furfine	2
5	Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation 2015 ·Investigative Ophthalmology & Visual Science ·Karen L. Tubridy,Michael H. Goldstein,(unknown),(unknown),Joseph Kovalchin,Eric S. Furfine,Abbie Celniker	1
6	A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis 2015 ·Eye & Contact Lens Science & Clinical Practice ·Michael H. Goldstein,Karen L. Tubridy,(unknown),Eric S. Furfine,(unknown),Joseph Kovalchin,(unknown),Gregory Zarbis‐Papastoitsis,(unknown),Anne Marie Salapatek,(unknown),Abbie Celniker	18
7	Optimized IL-6 Blockade for the Treatment of Diabetic Macular Edema 2014 ·Investigative Ophthalmology & Visual Science ·Michael Schmidt,(unknown),(unknown),Joseph Kovalchin,Eric S. Furfine	6
8	Preclinical Development of EBI-005: a Potent Interleukin-1 (IL-1) Receptor-1 (R1) Blocker for Topical Ocular Administration was Safe in GLP Toxicology Studies and Active in a Mouse Model of Dry Eye Disease (DED) 2013 ·Investigative Ophthalmology & Visual Science ·Eric S. Furfine,(unknown),David Escobar,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Joseph Kovalchin	2
9	Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface 2013 ·Structure ·Michael M. Schmidt,Sharon A. Townson,Amy Andreucci,Bracken M. King,(unknown),(unknown),Christian Dombrowski,(unknown),(unknown),(unknown),Joseph Kovalchin,David V. Erbe,K. Dane Wittrup,Eric S. Furfine,Thomas M. Barnes	92
10	Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin 2011 ·Clinical Cancer Research ·Anthony W. Tolcher,Christopher J. Sweeney,K. Papadopoulos,Amita Patnaik,E. Gabriela Chiorean,Alain C. Mita,Kamalesh K. Sankhala,Eric S. Furfine,Jochem Gokemeijer,Lisa Iacono,Cheryl A. Eaton,Bruce A. Silver,Monica Mita	67
11	Pharmacokinetics and Ocular Tissue Penetration of VEGF Trap After Intravitreal Injections in Rabbits 2006 ·Investigative Ophthalmology & Visual Science ·Eric S. Furfine,Alida Coppi,Ellen Koehler-Stec,(unknown),(unknown),Craig B Struble	15
12	VEGF Trap Both Prevents Experimental Choroidal Neovascularization and Causes Regression of Established Lesions in Non–Human Primates 2005 ·Investigative Ophthalmology & Visual Science ·Stanley J. Wiegand,(unknown),T. Michael Nork,Paul E. Miller,Christian Bueger,(unknown),J. Cao,Jesse M. Cedarbaum,George D. Yancopoulos,Eric S. Furfine	4
13	Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles 2005 ·Bioorganic & Medicinal Chemistry Letters ·John F. Miller,(unknown),Eric S. Furfine,Richard Hazen,István Káldor,David J. Reynolds,Ronald G. Sherrill,Andrew Spaltenstein	15
14	Exploration of the P1 SAR of aldehyde cathepsin K inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·John G. Catalano,David N. Deaton,Eric S. Furfine,Annie M. Hassell,Robert B. McFadyen,Aaron B. Miller,Larry R. Miller,Lisa M. Shewchuk,Derril H. Willard,Lois L. Wright	32
15	Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease 2002 ·Bioorganic & Medicinal Chemistry Letters ·Wieslaw M. Kazmierski,Eric S. Furfine,Andrew Spaltenstein,Lois L. Wright	39
16	1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivobreakdown → 1997 ·Journal of Biological Chemistry ·Edward P. Garvey,Jeffrey A. Oplinger,Eric S. Furfine,(unknown),Ferenc László,B.J.R. Whittle,Richard G. Knowles	727
17	Purification and inhibitor screening of human nitric oxide synthase isozymes 1996 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Edward P. Garvey,Eric S. Furfine,Paula Sherman	10
18	Two-step binding mechanism for HIV protease inhibitors 1992 ·Biochemistry ·Eric S. Furfine,(unknown),(unknown),Johann Leban,Thomas Spector,David Porter	54
19	Human immunodeficiency virus reverse transcriptase ribonuclease H: specificity of tRNALys3-primer excision 1991 ·Biochemistry ·Eric S. Furfine,John E. Reardon	62
20	A single-straded RNA copy of theGiardia lambliavirus double-stranded RNA genome is present in the infectedGiardia lamblia 1989 ·Nucleic Acids Research ·Eric S. Furfine,Theodore C. White,Alice L. Wang,Ching C. Wang	25

About Eric S. Furfine

Eric S. Furfine is a scholar working on Virology, Infectious Diseases and Biophysics, having authored 73 papers that have together received 4.3k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (32 papers), HIV Research and Treatment (24 papers) and Nitric Oxide and Endothelin Effects (10 papers). The work is most often cited by research in Virology (1.1k citations), Infectious Diseases (1.2k citations) and Biochemistry (439 citations). Eric S. Furfine has collaborated with scholars based in United States, United Kingdom and India. Frequent co-authors include Edward P. Garvey, Jeffrey A. Oplinger, John E. Reardon, Richard G. Knowles, B.J.R. Whittle, Ferenc László, Lois L. Wright, Andrew Spaltenstein, Barbara Maschera and Edward D. Blair. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact